Effect of Thyroid Disorders in Liver Diseases

• Sponsor: Assiut University (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT06071923
• Collaborator: (none)
• Enrollment: 140
• Anticipated Duration (Months): 13

Study Details

Study Description

Brief Summary

Aims of the Research

1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD).

2. To detect hepatic risk in subclinical and clinical hypothyroidism .

3. To detect early liver disorders in thyroid disorders using fibroscan .

Condition or Disease	Intervention/Treatment	Phase
Fatty Liver Disease	Device: Fibroscan

Detailed Description

Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time.

considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future..

Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis.

In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism.

The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH.

In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction.

Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Study Design

• Study Type: Observational
• Anticipated Enrollment: 140 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Effect of Thyroid Disorders in Metabolic Fatty Liver Changes
• Anticipated Study Start Date: Jan 1, 2024
• Anticipated Primary Completion Date: Jan 1, 2025
• Anticipated Study Completion Date: Feb 1, 2025

Outcome Measures

Primary Outcome Measures

1. Detect correlation between hyperthyroid diseases and NASH . [Baseline]

   Test the patients of thyroid disorders for metabolic fatty liver changes

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• The study will include thyroid patients over one year duration ( age above 18 years old

Exclusion Criteria:

1. History of liver failure or patient known to have congenital liver disease.

2. Medications associated with weight gain .

3. Patients who have diabetes mellitus.

4. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis.

5. Patients on antistatin.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Tasneem Mohammed Ali, Principal investigator, Assiut University
• ClinicalTrials.gov Identifier: NCT06071923
• Other Study ID Numbers: 04-2023-200396
• First Posted: Oct 10, 2023
• Last Update Posted: Oct 10, 2023
• Last Verified: Oct 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Liver Diseases; Fatty Liver; Thyroid Diseases

Study Results

No Results Posted as of Oct 10, 2023